154 related articles for article (PubMed ID: 36085118)
1. The oncological outcomes of isolated limb perfusion and neo-adjuvant radiotherapy in soft tissue sarcoma patients - A nationwide multicenter study.
van Praag VM; Fiocco M; Bleckman RF; van Houdt WJ; Haas RLM; Verhoef C; Grunhagen DJ; van Ginkel RJ; Bonenkamp JJ; van de Sande MAJ
Eur J Surg Oncol; 2023 Feb; 49(2):339-344. PubMed ID: 36085118
[TBL] [Abstract][Full Text] [Related]
2. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
[TBL] [Abstract][Full Text] [Related]
3. Oncological outcome after hyperthermic isolated limb perfusion for primarily unresectable versus locally recurrent soft tissue sarcoma of extremities.
Vassos N; Brunner M; Perrakis A; Göhl J; Grützmann R; Hohenberger W; Croner RS
Surg Oncol; 2020 Dec; 35():162-168. PubMed ID: 32882523
[TBL] [Abstract][Full Text] [Related]
4. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
Lejeune FJ; Pujol N; Liénard D; Mosimann F; Raffoul W; Genton A; Guillou L; Landry M; Chassot PG; Chiolero R; Bischof-Delaloye A; Leyvraz S; Mirimanoff RO; Bejkos D; Leyvraz PF
Eur J Surg Oncol; 2000 Nov; 26(7):669-78. PubMed ID: 11078614
[TBL] [Abstract][Full Text] [Related]
5. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors.
Vrouenraets BC; Keus RB; Nieweg OE; Kroon BB
J Surg Oncol; 1997 Jun; 65(2):88-94. PubMed ID: 9209519
[TBL] [Abstract][Full Text] [Related]
6. [Limb perfusion in soft tissue sarcomas: twenty years of experience].
Hoven-Gondrie ML; Bastiaannet E; van Ginkel RJ; Pras EB; Suurmeijer A; Hoekstra HJ
Ned Tijdschr Geneeskd; 2013; 157(30):A6148. PubMed ID: 23890169
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
[TBL] [Abstract][Full Text] [Related]
8. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy.
Thijssens KM; van Ginkel RJ; Pras E; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2006 Apr; 13(4):518-24. PubMed ID: 16485147
[TBL] [Abstract][Full Text] [Related]
9. Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resection.
Jakob J; Tunn PU; Hayes AJ; Pilz LR; Nowak K; Hohenberger P
J Surg Oncol; 2014 Jun; 109(8):786-90. PubMed ID: 24619722
[TBL] [Abstract][Full Text] [Related]
10. Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma.
Jakob J; Hohenberger P
Cancer; 2016 Sep; 122(17):2624-32. PubMed ID: 27197621
[TBL] [Abstract][Full Text] [Related]
11. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF
J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638
[TBL] [Abstract][Full Text] [Related]
12. Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients.
Deroose JP; van Geel AN; Burger JW; Eggermont AM; Verhoef C
J Surg Oncol; 2012 May; 105(6):563-9. PubMed ID: 22020863
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of isolated limb perfusion in the treatment of extremity soft tissue sarcoma: a systematic review.
Bhangu A; Broom L; Nepogodiev D; Gourevitch D; Desai A
Eur J Surg Oncol; 2013 Apr; 39(4):311-9. PubMed ID: 23351681
[TBL] [Abstract][Full Text] [Related]
14. Long-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremity.
Hoven-Gondrie ML; Thijssens KM; Van den Dungen JJ; Loonstra J; van Ginkel RJ; Hoekstra HJ
Ann Surg Oncol; 2007 Jul; 14(7):2105-12. PubMed ID: 17457649
[TBL] [Abstract][Full Text] [Related]
15. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
[TBL] [Abstract][Full Text] [Related]
16. Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study.
Huis In 't Veld EA; Grünhagen DJ; Verhoef C; Smith HG; van Akkooi ACJ; Jones R; van Coevorden F; Hayes AJ; van Houdt WJ
Eur J Cancer; 2017 Nov; 85():114-121. PubMed ID: 28918185
[TBL] [Abstract][Full Text] [Related]
17. Isolated limb perfusion is an effective treatment modality for locally advanced Kaposi sarcoma of the extremities.
Boere T; Huis In 't Veld EA; Deroose JP; van Ginhoven TM; Wouters MWJM; Grünhagen DJ; Verhoef C; van Houdt WJ
Eur J Surg Oncol; 2020 Jul; 46(7):1315-1319. PubMed ID: 32359920
[TBL] [Abstract][Full Text] [Related]
18. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation.
van Ginkel RJ; Thijssens KM; Pras E; van der Graaf WT; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2007 Apr; 14(4):1499-506. PubMed ID: 17253101
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of isolated limb perfusion in advanced soft tissue sarcoma of the extremity.
Olofsson R; Bergh P; Berlin O; Engström K; Gunterberg B; Hansson M; Lindnér P; Mattsson J
Ann Surg Oncol; 2012 Jun; 19(6):1800-7. PubMed ID: 22219068
[TBL] [Abstract][Full Text] [Related]
20. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
Eggermont AM; Schraffordt Koops H; Liénard D; Kroon BB; van Geel AN; Hoekstra HJ; Lejeune FJ
J Clin Oncol; 1996 Oct; 14(10):2653-65. PubMed ID: 8874324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
